RESPONSE
OFFICIAL TITLE: PREDICTORS OF 18F-FDG PET-DRIVEN DISEASE DETECTION IN HER2+ EARLY BREAST CANCER PATIENTS. A SUB-STUDY OF THE PHERGAIN CLINICAL TRIAL
STUDY DETAILS
THE RESPONSE PROJECT IS A SUB-STUDY OF THE PHERGAIN CLINICAL TRIAL, AIMING AT EXPLORING THE ASSOCIATION BETWEEN CLINICAL, MOLECULAR, AND METABOLIC TUMOR CHARACTERISTICS AND THE PROBABILITY OF DISEASE DETECTION BY 18F-FDG PET (PET) IN ALL THE HER2+ EARLY BREAST CANCER (EBC) PATIENTS SCREENED IN THE PHERGAIN TRIAL. AS INITIAL ESTIMATIONS ON SCREENING FAILURES PATIENTS BY PET (PET[-]) WERE UNDERESTIMATED, A SELECTED COHORT OF 21 PET[-] AND 21 PET[+] MATCHED PATIENTS FROM THE PHERGAIN TRIAL WERE EVALUATED WITH THE INTENTION OF ACHIEVING AN APPROPRIATE PATIENT SELECTION USING A RESPONSE-ADAPTED STRATEGY IN THE HER2+ EBC.
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
BREAST
Sub-study
377
patients included in the PHERGain study; selected cohort of 21 PET[-] and 21 PET[+] matched patients
56
Spain, Portugal, France,
UK, Italy, Belgium,
Germany
Analysis performed